Naringin rescued the TNF-α-induced inhibition of osteogenesis of bone marrow-derived mesenchymal stem cells by depressing the activation of NF-кB signaling pathway

Immunologic Research

Volumn 62, Issue 3, 2015, Pages 357-367

  Cao, Xvhai ^a   Lin, Weilong ^a   Liang, Chengwei ^a   Zhang, Dong ^a   Yang, Fengjian ^a   Zhang, Yan ^a   Zhang, Xuelin ^a   Feng, Jianyong ^a   Chen, Cong ^a  

^a HUADONG HOSPITAL AFFILIATED TO FUDAN UNIVERSITY   (China)

Author keywords

Inflammation; Naringin; Nuclear factor kappa B (NF B); Osteogenesis; Tumor necrosis factor (TNF )

Indexed keywords

ALKALINE PHOSPHATASE; AURANTIIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; FLAVANONE DERIVATIVE; I KAPPA B; NF-KAPPAB INHIBITOR ALPHA; OSTERIX PROTEIN, MOUSE; RELA PROTEIN, MOUSE; RUNX2 PROTEIN, MOUSE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; GENE; IN VITRO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; OSX GENE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SUBUNIT; RUNX2 GENE; SIGNAL TRANSDUCTION; STEM CELL CULTURE; ANIMAL; BIOSYNTHESIS; BONE MARROW CELL; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; MESENCHYMAL STROMA CELL; PHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BONE MARROW CELLS; CELL SURVIVAL; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FLAVANONES; I-KAPPA B PROTEINS; MESENCHYMAL STROMAL CELLS; MICE; OSTEOGENESIS; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84931567261     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-015-8665-x     Document Type: Article

References (40)

1. Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 2004;15(1):49–60.
2. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA. 1989;86(7):2336–40.
3. Kato K, Nakane A, Minagawa T, Kasai N, Yamamoto K, Sato N, et al. Human tumor necrosis factor increases the resistance against Listeria infection in mice. Med Microbiol Immunol. 1989;178(6):337–46.
4. Hauser T, Frei K, Zinkernagel RM, Leist TP. Role of tumor necrosis factor in Listeria resistance of nude mice. Med Microbiol Immunol. 1990;179(2):95–104.
5. Blanchard DK, Friedman H, Klein TW, Djeu JY. Induction of interferon-gamma and tumor necrosis factor by Legionella pneumophila: augmentation of human neutrophil bactericidal activity. J Leukoc Biol. 1989;45(6):538–45.
6. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol. 2001;19:163–96. doi:10.1146/annurev.immunol.19.1.163.
7. Hommes DW, van de Heisteeg BH, van der Spek M, Bartelsman JF, van Deventer SJ. Infliximab treatment for Crohn’s disease: one-year experience in a Dutch Academic Hospital. Inflamm Bowel Dis. 2002;8(2):81–6.
8. McLean RR. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep. 2009;7(4):134–9.
9. Glass GE, Chan JK, Freidin A, Feldmann M, Horwood NJ, Nanchahal J. TNF-alpha promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells. Proc Natl Acad Sci USA. 2011;108(4):1585–90. doi:10.1073/pnas.1018501108.
10. Tocci A, Forte L. Mesenchymal stem cell: use and perspectives. Hematol J. 2003;4(2):92–6. doi:10.1038/sj.thj.6200232.
11. Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood. 2004;103(5):1669–75. doi:10.1182/blood-2003-05-1670.
12. Chang YJ, Shih DT, Tseng CP, Hsieh TB, Lee DC, Hwang SM. Disparate mesenchyme-lineage tendencies in mesenchymal stem cells from human bone marrow and umbilical cord blood. Stem Cells. 2006;24(3):679–85. doi:10.1634/stemcells.2004-0308.
13. Wang EA, Israel DI, Kelly S, Luxenberg DP. Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors. 1993;9(1):57–71.
14. Yu S, Zhu K, Lai Y, Zhao Z, Fan J, Im HJ, et al. atf4 promotes beta-catenin expression and osteoblastic differentiation of bone marrow mesenchymal stem cells. Int J Biol Sci. 2013;9(3):256–66. doi:10.7150/ijbs.5898.
15. Wong RW, Rabie B, Bendeus M, Hagg U. The effects of Rhizoma Curculiginis and Rhizoma Drynariae extracts on bones. Chin Med. 2007;2:13. doi:10.1186/1749-8546-2-13.
16. Shin YW, Bok SH, Jeong TS, Bae KH, Jeoung NH, Choi MS, et al. Hypocholesterolemic effect of naringin associated with hepatic cholesterol regulating enzyme changes in rats. Int J Vitam Nutr Res. 1999;69(5):341–7.
17. Mahmoud AM, Ashour MB, Abdel-Moneim A, Ahmed OM. Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine production in high fat fed/streptozotocin-induced type 2 diabetic rats. J Diabetes Complic. 2012;26(6):483–90. doi:10.1016/j.jdiacomp.2012.06.001.
18. Wong KC, Pang WY, Wang XL, Mok SK, Lai WP, Chow HK, et al. Drynaria fortunei-derived total flavonoid fraction and isolated compounds exert oestrogen-like protective effects in bone. Br J Nutr. 2013;110(3):475–85. doi:10.1017/S0007114512005405.
19. Gilbert L, He X, Farmer P, Boden S, Kozlowski M, Rubin J, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology. 2000;141(11):3956–64. doi:10.1210/endo.141.11.7739.
20. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–7.
21. Akiyama K, You YO, Yamaza T, Chen C, Tang L, Jin Y, et al. Characterization of bone marrow derived mesenchymal stem cells in suspension. Stem Cell Res Ther. 2012;3(5):40. doi:10.1186/scrt131.
22. Peng CF, Han YL, Jie D, Yan CH, Jian K, Bo L, et al. Overexpression of cellular repressor of E1A-stimulated genes inhibits TNF-alpha-induced apoptosis via NF-kappaB in mesenchymal stem cells. Biochem Biophys Res Commun. 2011;406(4):601–7. doi:10.1016/j.bbrc.2011.02.100.
23. Zhang P, Dai KR, Yan SG, Yan WQ, Zhang C, Chen DQ, et al. Effects of naringin on the proliferation and osteogenic differentiation of human bone mesenchymal stem cell. Eur J Pharmacol. 2009;607(1–3):1–5.
24. Butler DL, Gooch C, Kinneberg KR, Boivin GP, Galloway MT, Nirmalanandhan VS, et al. The use of mesenchymal stem cells in collagen-based scaffolds for tissue-engineered repair of tendons. Nat Protoc. 2010;5(5):849–63. doi:10.1038/nprot.2010.14.
25. Jimi E, Aoki K, Saito H, D’Acquisto F, May MJ, Nakamura I, et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med. 2004;10(6):617–24. doi:10.1038/nm1054.
26. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 2003;14(3–4):185–91.
27. Endres R, Luz A, Schulze H, Neubauer H, Futterer A, Holland SM, et al. Listeriosis in p47(phox-/-) and TRp55-/- mice: protection despite absence of ROI and susceptibility despite presence of RNI. Immunity. 1997;7(3):419–32.
28. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004;6(3):203–8. doi:10.1016/j.ccr.2004.09.003.
29. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 2000;15(1):2–12. doi:10.1080/14041040009362546.
30. Roggia C, Tamone C, Cenci S, Pacifici R, Isaia GC. Role of TNF-alpha producing T-cells in bone loss induced by estrogen deficiency. Minerva Med. 2004;95(2):125–32.
31. Chen X, Hu C, Wang G, Li L, Kong X, Ding Y, et al. Nuclear factor-kappaB modulates osteogenesis of periodontal ligament stem cells through competition with beta-catenin signaling in inflammatory microenvironments. Cell Death Dis. 2013;4:e510. doi:10.1038/cddis.2013.14.
32. Kong X, Liu Y, Ye R, Zhu B, Zhu Y, Liu X, et al. GSK3beta is a checkpoint for TNF-alpha-mediated impaired osteogenic differentiation of mesenchymal stem cells in inflammatory microenvironments. Biochim Biophys Acta. 2013;1830(11):5119–29. doi:10.1016/j.bbagen.2013.07.027.
33. Fuhr U, Kummert AL. The fate of naringin in humans: A key to grapefruit juice–drug interactions? Clin Pharmacol Ther. 1995;58(4):365–73. doi:10.1016/0009-9236(95)90048-9.
34. Wu JB, Fong YC, Tsai HY, Chen YF, Tsuzuki M, Tang CH. Naringin-induced bone morphogenetic protein-2 expression via PI3 K, Akt, c-Fos/c-Jun and AP-1 pathway in osteoblasts. Eur J Pharmacol. 2008;588(2–3):333–41. doi:10.1016/j.ejphar.2008.04.030.
35. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286(5446):1946–9.
36. Wong RW, Rabie AB. Statin collagen grafts used to repair defects in the parietal bone of rabbits. Br J Oral Maxillofac Surg. 2003;41(4):244–8.
37. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun. 2000;271(3):688–92. doi:10.1006/bbrc.2000.2697.
38. Wong RW, Rabie AB. Effect of naringin on bone cells. J Orthop Res. 2006;24(11):2045–50. doi:10.1002/jor.20279.
39. Liu M, Li Y, Yang ST. Effects of naringin on the proliferation and osteogenic differentiation of human amniotic fluid-derived stem cells. J Tissue Eng Regen Med. 2014;. doi:10.1002/term.1911.
40. Jain M, Parmar HS. Evaluation of antioxidative and anti-inflammatory potential of hesperidin and naringin on the rat air pouch model of inflammation. Inflamm Res. 2011;60(5):483–91. doi:10.1007/s00011-010-0295-0.